US20070269858A1 - Combinatorial Biology - Google Patents

Combinatorial Biology Download PDF

Info

Publication number
US20070269858A1
US20070269858A1 US11/763,966 US76396607A US2007269858A1 US 20070269858 A1 US20070269858 A1 US 20070269858A1 US 76396607 A US76396607 A US 76396607A US 2007269858 A1 US2007269858 A1 US 2007269858A1
Authority
US
United States
Prior art keywords
starter units
solid support
collection
enzymatic machinery
starter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/763,966
Inventor
Kevin Jarrell
Matthew Shair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Boston University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/225,990 external-priority patent/US6358712B1/en
Application filed by Individual filed Critical Individual
Priority to US11/763,966 priority Critical patent/US20070269858A1/en
Publication of US20070269858A1 publication Critical patent/US20070269858A1/en
Assigned to PRESIDENT AND FELLOWS OF HARVARD COLLEGE reassignment PRESIDENT AND FELLOWS OF HARVARD COLLEGE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHAIR, MATTHEW D.
Assigned to TRUSTEES OF BOSTON UNIVERSITY reassignment TRUSTEES OF BOSTON UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JARRELL, KEVIN A.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • C12N15/1027Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Definitions

  • peptidomimetic libraries include phthalimido libraries (WO 97/22594), thiophene libraries (WO 97/40034), benzodiazopene libraries (U.S. Pat. No.
  • the present invention provides a unique method in which both the tools provided by nature and modern organic synthesis can be utilized.
  • the present invention provides a method for merging combinatorial biosynthesis incorporated above with techniques of synthetic organic chemistry.
  • this method combinatorial biology, involves 1) providing “starter units”, wherein the starter units are capable of being accepted by the modular biosynthetic enzymatic machinery, and have incorporated therein a “functional handle” capable of reacting with specific functionality present on a solid support; 2) feeding these “starter units” into the modular biosynthetic enzymatic machinery, in vivo or in vitro, to obtain complex template molecules; and 3) further functionalizing the complex template molecules using synthetic organic chemistry to provide a collection of complex “unnatural” natural products having structural, topological, stereochemical and functional diversity.
  • the starter units are attached to solid support units prior to feeding the starter units into the modular biosynthetic enzymatic machinery, and thus the support bound starter units are fed into the biosynthetic enzymatic machinery to generate a collection of complex template structures.
  • These template structures thus generated can then be further functionalized using synthetic organic chemistry, or can be further functionalized using any combination of synthetic organic chemistry and reintroduction into the biosythetic enzymatic machinery.
  • the starter units are fed to the modular biosynthetic enzymatic machinery prior to being attached to the solid support, and thus template structures are generated.
  • specific functionalities can also be incorporated into the template structures via the original starter unit capable of being recognized by an antibody and then purified.
  • these templates can then be attached to solid support units and further functionalized using synthetic organic chemistry or any combination of synthetic organic chemistry and the biosynthetic enzymatic machinery.
  • FIG. 1 depicts the biosynthesis of several erythromycin derivatives using several different starter units.
  • FIG. 2 depicts potential starter units with functional handles classified by the biosynthetic pathway.
  • FIG. 3 depicts the functionalization of an iodoaryl compound to generate an arylacetylene via Sonogashiro/Castro-Stephens coupling reaction.
  • FIG. 4 depicts certain preferred embodiments of the method of the present invention.
  • FIGS. 5A through 5C depict specific complex template structures capable of further diversification using synthetic organic chemistry or biosynthetic pathways.
  • this method involves 1) providing “starter units”, wherein the starter units are capable of being accepted by the modular biosynthetic enzymatic machinery, and have incorporated therein a “functional handle” capable of reacting with specific functionality present on a solid support; 2) feeding these “starter units” into the modular biosynthetic enzymatic machinery, in vivo or in vitro, to obtain complex template molecules; and 3) further functionalizing the complex template molecules using synthetic organic chemistry to provide a collection of complex “unnatural” natural products having structural, topological, stereochemical and functional diversity.
  • starter unit comprises any compound that can be incorporated into the biosynthetic pathway.
  • certain biosynthetic enzymes such as polyketide synthases, utilize two different classes of “starter units”, specifically “initiator” molecules and “extender“molecules, typically acetates or propionates.
  • starter units specifically “initiator” molecules and “extender“molecules, typically acetates or propionates.
  • initiator” orextender qualifies as a “starter” molecule.
  • the starter units have incorporated therein a functional handle, they, or any of the products generated from these starter units, are capable of being attached to solid support units at any stage in the combinatorial biosynthetic pathway.
  • the starter units are attached to solid support units prior to feeding the starter units into the modular biosynthetic enzymatic machinery, and thus the support bound starter units are fed into the biosynthetic enzymatic machinery to generate a collection of complex template structures.
  • These template structures thus generated can then be further functionalized using synthetic organic chemistry, or can be further functionalized using any combination of synthetic organic chemistry and reintroduction into the biosynthetic enzymatic machinery.
  • the starter units are fed to the modular biosynthetic enzymatic machinery prior to being attached to the solid support, and thus template structures are generated.
  • specific functionalities can also be incorporated into the template structures via the original starter unit capable of being recognized by an antibody and then purified.
  • these templates can then be attached to solid support units and further functionalized using synthetic organic chemistry or any combination of synthetic organic chemistry and the biosynthetic enzymatic machinery.
  • the present invention represents a broadening of the concept of combinatorial biosynthesis to incorporate the advantages of organic synthetic techniques on the solid phase to generate increasingly complex “unnatural” natural products.
  • Various characteristics of the starter units and the reactions utilized in preferred embodiments of the present invention are discussed in more detail below; certain examples of the method of the present invention are also presented.
  • the inventive combinatorial biology methods may be applied to any biosynthetic pathway in which the synthetic enzymes will accept inventive starter molecules.
  • the starter molecules are provided to living cells in which the synthetic enzymes are operating, and synthetic reactions in accordance with the present invention are performed in vivo.
  • the biosynthetic pathway may be reproduced in vitro, and the starter molecules may be provided to the synthetic enzymes in that context.
  • Preferred biosynthetic pathways to which the inventive technology may be applied include the animal fatty acid synthase pathway, the polyketide synthase pathway, the peptide synthetase pathway, and the terpene (or isoprenoid) synthase pathway.
  • the naturally-occurring synthetic enzymes are employed and are simply provided with non-natural starter molecules as described herein.
  • Preferred embodiments of the present invention utilize such modified enzymes, and preferably libraries of modified enzymes, to catalyze synthetic reactions with inventive starter molecules.
  • the system described in the above-mentioned “Improved DNA Cloning” patent application can be utilized to generate a library of class I polyketide synthase enzymes in which a particular “AT” domain responsible for choosing an inventive altered starter molecule has been shuffled to a variety of different positions in the molecule. Exposure of such an enzyme library to the appropriate collection of natural and inventive starter and extender molecules will result in incorporation of inventive molecules at various locations in the polyketide-type compound being synthesized, so that a wide variety of different polyketide-type molecules can be produced by subsequent combinatorialization of the compounds generated by the synthetic enzyme.
  • the method of the present invention utilizes any combination of enzymatic machinery that can be employed for specific classes of biosynthetic reaction pathways.
  • starter units that will be utilized in the synthesis, consideration must also be made to the desired biosynthetic pathway to employ, and thus a desired family of compounds to be synthesized.
  • specific biosynthetic pathways such as polyketide synthases and peptide synthases, utilize particular starter units known to be accepted by the modular enzymes to produce a variety of natural products.
  • carboxylic acid building blocks having differing functional moieties such as methyl, ethyl, propyl groups are utilized by modular polyketide synthases to yield topologically, functionally and stereochemically diverse structures such as 6 -deoxyerythronolide B and tylactone (see, Khosla, Chem. Rev. 1997, 97, 2577).
  • functionalized thioesters are utilized to generate a series of derivatives having structures similar to erythromycin (see, Khosla, Chem. Rev. 1997, 97, 2577).
  • the modular enzymes that are produced by the shuffling may not result in the ability to predict the specific starter units that will be incorporated into the enzymatic machinery.
  • the ability of a desired or random set of starter units to become attached to the solid support and subsequently diversified using combinatorial techniques (split-pool synthesis) becomes particularly important in identifyingfunctional starter units.
  • each of the starter units provided must be capable of being accepted by the enzymes “machinery”, and thus the functionality and structural topology must be compatible with the biosynthetic pathway.
  • the functionality and structural topology must be compatible with the biosynthetic pathway.
  • FIG. 2 it would be desirable for a terpene-based pathway to utilize functionalized derivatives of a famasyl pyrophosphate analog.
  • an amino-acid based pathway peptide synthases
  • FIG. 2 additionally provides a collection of suitable “starter units” classified according to their utility in a specific biosynthetic pathway.
  • these units can be derivatized and combinatorialized at a stage prior to feeding the units into the enzymatic machinery to produce structures having more diverse functionalities, or to produce structures having more complex topology.
  • any structure may be utilized as a “starter unit”, regardless of the complexity and functional diversity of the compound, provided that the starter unit is capable of being utilized by the enzymatic pathway.
  • each of the “starter units” that are fed into the modular biosynthetic enzymatic “machinery” preferably contains a suitable functional “handle” capable of attachment to functionality present on the solid phase.
  • FIG. 2 also depicts exemplary starter units having alkynes incorporated therein as functional handles. This can be effected by modifying the starter units that will be utilized in a particular biosynthetic pathway to incorporate the specific desired functionality for coupling to the solid support.
  • attachment to the solid phase can occur prior to feeding the starter units into the enzymatic machinery, or after feeding the starter units into the enzymatic machinery to generate complex template structures to be attached to the solid support. Because attachment can occur prior to or after exposure to the enzymatic machinery, it is particularly preferred that the functional handle is chemically robust and thus is capable of withstanding any of the reaction conditions encountered in the enzymatic machinery. For this reason, particularly robust functionalities such as alkynes, olefins and iodoalkenes, are particularly preferred, although the method of the present invention is not limited to these functionalities.
  • the starter units utilized in the present invention have alkyne functionalities incorporated therein as handles for attachment to the solid support.
  • FIG. 3 depicts the use of the Sonagashiro/Castro-Stephens reaction, in which unactivated aryl halides react with copper acetylides to give good yields of arylacetylenes, for the conversion of an aryl iodide to an aryl acetylene in the iodo substituted aryl thioester derivative.
  • the starter units can either be fed directly into the enzymatic machinery or coupled directly to the solid support.
  • the starter unit or the template structure is utilized for coupling to the solid support, (which, as one of ordinary skill in the art will realize, also has an alkyne, or other desirable functionality, bound thereto via a cleavable bond utilizing standard synthetic organic techniques) the two alkynes incorporated can then be coupled, in a preferred embodiment, using a Glaser Coupling reaction.
  • the addition of copper (II) acetate to the reaction medium effects coupling of the two components to yield a solid support having bound thereto a starter unit, or a template structure, via a diyne functionality.
  • suitable functional handles which can also be easily incorporated into starter units and solid support units using standard techniques of synthetic organic chemistry, include olefins and iodoalkenes.
  • coupling of the components can be effected using olefin metathesis and Stille Coupling reactions, respectively.
  • FIG. 4 refers to preferred embodiments of the present invention and a discussion of each of these embodiments with reference to FIG. 4 is presented below.
  • the selected starter units having the functional handles incorporated therein can be fed directly into the mutated biosynthetic enzymatic machinery.
  • a unique template compound can be obtained and at this stage can be purified, preferably using an antibody recognition element, or can also be attached to a solid support unit.
  • the template could be reintroduced into the enzymatic machinery (same or different) to thus obtain a modified template.
  • the template could be utilized in split-pool organic synthesis to generate combinatorial libraries of complex “unnatural” natural products.
  • the selected starter units having the functional handles incorporated therein can be attached to the solid support prior to being exposed to the biosynthetic enzymatic machinery.
  • a collection of starter units could be generated using combinatorial synthetic organic chemistry.
  • the starter units are transformed into a support bound template structure.
  • the template structure resulting from an initial exposure to a single biosynthetic pathway could be reexposed to the same biosynthetic or to another biosynthetic pathway to further modify the structure.
  • the solid support template structure could be diversified using split and pool techniques and synthetic organic chemistry. As one of ordinary skill in the art will realize, any combination of the enzymatic machinery and split-pool synthetic organic techniques can be employed to increase the structural, functional, topological and stereochemical diversity to generate a collection of unique “unnatural” natural products.
  • either split-pool or parallel synthesis methods can be employed at each stage of the inventive method to provide a desired collection of compounds.
  • a parallel synthesis technique is preferably utilized so that the product resulting from the enzymatic machinery can be identified using spatial encoding methods.
  • subsequent identification of compounds using standard methods such as nuclear magnetic resonance spectroscopy or mass spectrometry can also be employed to identify specific compounds.
  • the identification of individual compounds may be prohibitively time consuming and therefore a spatial encoding method may be more particularly preferred.
  • the template structures are generated in solution, rather than on a solid support unit.
  • a parallel synthesis technique is utilized, in which all of the products are assembled separately in their own reaction vessels.
  • a microtitre plate containing n rows and m columns of tiny wells which are capable of holding a few milliliters of the solvent in which the reaction will occur, is utilized.
  • a solid phase synthesis technique is utilized for the biosynthesis of the templates and the diversified structures, or alternatively for the synthesis of the diversified structures produced from template structures generated in solution as described above.
  • the starter units or the template structures are attached to the solid phase directly or though a linking unit, depending on the stage of the procedure a solid phase synthesis is desired.
  • Advantages of solid phase techniques most particularly at the stage when the template structures are functionalized using synthetic organic techniques, include the ability to more easily conduct multi-step reactions and the ability to drive reactions to completion because excess reagents can be utilized and the unreacted reagent washed away.
  • the solid support templates or starter units can be divided into n vessels, where n represents the number species of reagent A, or the number of different biosynthetic pathways created by the shuffling procedure, to be reacted with the template structures or starter units.
  • n represents the number species of reagent A, or the number of different biosynthetic pathways created by the shuffling procedure
  • the contents from n vessels are combined and then split into m vessels, where m represents the number of species of reagent B, or the number of different biosynthetic pathways created by the shuffling procedure, to be reacted with the scaffold structures. This procedure is repeated until a desired collection of structures is obtained to yield a library of “unnatural” natural products.
  • solid phase techniques in the present invention may also include the use of a specific encoding technique.
  • Specific encoding techniques have been reviewed by Czarnik. (Czarnik, A. W., Current Opinion in Chemical Biology, 1997, 1, 60.)
  • an encoding technique involves the use of a particular “identifying agent” attached to the solid support, which enables the determination of the structure of a specific library member without reference to its spatial coordinates.
  • identifying agent attached to the solid support
  • Examples of particularly preferred alternative encoding techniques that can be utilized in the present invention include, but are not limited to, spatial encoding techniques, graphical encoding techniques, including the “tea bag” method, chemical encoding methods, and spectrophotometric encoding methods.
  • Spatial encoding refers to recording a reaction's history based on its location.
  • Graphical encoding techniques involve the coding of each synthesis platform to permit the generation of a relational database.
  • Examples of preferred spectrophotometic encoding methods include the use of mass spectroscopy, fluorescence emission, and nuclear magnetic resonance spectroscopy.
  • chemical encoding methods are utilized, which uses the structure of the reaction product to code for its identity. Decoding using this method can be performed on the solid phase or off of the solid phase.
  • One of ordinary skill in the art will realize that the particular encoding method to be used in the present invention must be selected based upon the number of library members desired, and the reaction chemistry employed.
  • Subsequent characterization of the library members which can include either the scaffolds obtained after the biosynthetic pathway or the complex molecules obtained after diversification using synthetic organic chemistry, can be performed using standard analytical techniques, such as mass spectrometry, Nuclear Magnetic Resonance Spectroscopy, and gas chromatography.
  • analytical techniques such as mass spectrometry, Nuclear Magnetic Resonance Spectroscopy, and gas chromatography.
  • FIG. 5 depicts specific natural products which are capable of being generated using the method of the present invention, or alternatively derivatives of which are also capable of being generated using the method of the present invention.
  • these structures exemplify the variety of sites of latent functionality at which diversification can be achieved using synthetic combinatorial techniques. As discussed previously, this can be achieved using solution or solid phase methods, using parallel or split-pool techniques. It is particularly preferred, however, to utilize solid phase split-pool techniques. Examples of specific reactions to which some or all of the systems depicted in FIG.
  • nucleophiles such as primary and secondary amines
  • functionalization of free hydroxyls with electrophiles for examples isocyanates, anhydrides, or acid chlorides
  • epoxides with nucleophiles, such as amines, under ytterbium catalysis
  • functionalization of aromatic rings specifically functionalization at an aryl iodide by conversion to such structures as amines, amides, aromatic rings, alkenes, alkynes, and heterocycles using palladium catalyzed chemistry such as Buchwald-Hartwig aminations, Heck and Stille couplings, Sonogashira/Castro-Stephens couplings, Suzuki and Stille couplings, and carbonylations.
  • resulting aryl alkynes can undergo rhodium-catalyzed hydroacylation and azide cycloaddition and nitrone and nitrile oxide cycloadditions.
  • Other examples of diversification reactions at potential sites include reactions at amines and amides.
  • amides may be functionalized using a Mitsunobu reaction to generate alcohols such as straight chain, branched, and cyclic alcohols.
  • biomolecules such as polysaccharides, nucleic acids, or peptides
  • the methods, compounds and libraries generated by the method of the present invention can be utilized in various disciplines.
  • the complex molecules generated in the method of the present invention may modulate the biological activity of a biological target, such as a protein, nucleic acid, lipid or combination thereof.
  • the compounds generated by the method of the invention are utilized in chemical genetics assays to alter, i.e. inhibit or initiate, the action of such biological molecules.
  • the compounds may be used in in vitro assays, or any other system that allows detection of a chemical or biological function.
  • one or more inventive compounds is contacted with a biological target having a detectable biochemical activity.
  • biological targets include, for example, enzymes, receptors, subunits involved in the formation of multimeric complexes.
  • multimeric complex subunits may be characterized by catalytic capabilities (such as, for example, an ability to catalyze substrate conversion), or may alternatively be primarily active in binding to one or more other molecule.
  • the biological target can be provided in the form of a purified or semi-purified composition, a cell lysate, a whole cell or tissue, or even a whole organism.
  • the level of biochemical activity is detected in the presence of the compound, and a statistically significant change in the biochemical activity, relative to the level of biochemical activity in the absence of the compound, identifies the compound as a modulator, e.g. inhibitor or potentiator of the biological activity of the target protein.
  • a modulator e.g. inhibitor or potentiator of the biological activity of the target protein.
  • the effect of the chemical compound may be to alter the amount, in addition to or instead of the activity, of the particular biological target.
  • “Modulators”, therefore, are chemical compounds that alter the level of activity of a particular target molecule.
  • multiple compounds are assayed simultaneously in a high-throughput format, preferably allowing simultaneous analysis of at least 500,000 compounds, preferably at least 1,000,000 compounds, and most preferably at least or more than 2,000,000 compounds.
  • the compounds of the present invention may be utilized as a therapeutic agent for a particular medical condition.
  • a therapeutic agent for use in the present invention may include any pharmacologically active substances that produce a local or systemic effect in animals, preferably mammals, or humans. The term thus means any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or in the enhancement of desirable physical or mental development and conditions in an animal or human.
  • the therapeutic agent may be administered orally, topically or via injection by itself, or additionally may be provided as a pharmaceutical composition comprising the therapeutic agent and a biologically acceptable carrier.
  • inventive compositions can be, but are not limited to aqueous solutions, emulsions, creams, ointments, suspensions, gels, and liposomal suspensions.
  • Particularly preferred biologically acceptable carriers include but are not limited to water, saline, Ringer's solution, dextrose solution and solutions of ethanol, glucose, sucrose, dextran, mannose, mannitol, sorbitol, polyethylene glycol (PEG), phosphate, acetate, gelatin, collagen, Carbopol, and vegetable oils.
  • preservatives for example including but not limited to BHA, BHT, citric acid, ascorbic acid, and tetracycline.
  • buffering agents for example including but not limited to BHA, BHT, citric acid, ascorbic acid, and tetracycline.
  • the therapeutic agents of the presently claimed invention may also be incorporated or encapsulated in a suitable polymer matrix or membrane, thus providing a sustained-release delivery device suitable for implantation near the site to be treated locally.
  • the amount of the therapeutic agent required to treat any particular disorder will of course vary depending upon the nature and severity of the disorder, the age and condition of the subject, and other factors readily determined by one or ordinary skill in the art.
  • the compounds and libraries of the present invention may also be used for the development of cosmetics, food additives, pesticides, and lubricants to name a few.
  • the compounds and libraries of the present invention may also be used for the development of novel catalysts and materials.
  • the inventive compounds may be useful as ligands for transition metal catalysts and the inventive libraries may be useful for the rapid identification of novel ligands.
  • These compounds and libraries of compounds may also function by acting in concert with a particular transition metal catalyst to effect a particular desired chemical reaction.
  • the inventive compounds and libraries of compounds are also useful in the area of materials science. Because of the reactive moieties present in these compounds, molecules such as lipids and other polymeric materials may be attached and thus generate potentially important biomaterials.

Abstract

The present invention provides a method for merging combinatorial biosynthesis with techniques of synthetic organic chemistry. In general, this method, combinatorial biology, involves 1) providing “starter units”, wherein the starter units are capable of being accepted by the modular biosynthetic enzymatic machinery, and have incorporated therein a “functional handle” capable of reacting with specific functionality present on a solid support; 2) feeding these “starter units” into the modular biosynthetic enzymatic machinery, in vivo or in vitro, to obtain complex template molecules; and 3) further functionalizing the complex template molecules using synthetic organic chemistry to provide a collection of complex “unnatural” natural products having structural, topological, stereochemical and functional diversity. In one preferred embodiment, the starter units are attached to solid support units prior to being exposed to the modular biosynthetic enzymatic machinery. In another preferred embodiment, the starter units are exposed to the modular biosynthetic enzymatic machinery directly and thus the templates produced by the machinery are thus attached to the solid support. The starter units and the template structures used in the method of the present invention can both be diversified using synthetic organic chemistry.

Description

  • The present application claims priority to currently pending U.S. patent application Ser. No. 09/478,263, filed Jan. 5, 2000, which claims priority to Provisional Application U.S. Ser. No. 60/114,909, filed Jan. 5, 1999, the entire contents of each of which are incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • The ability of nature to produce small molecules having both structural complexity and biological potency has led to the development of countless number of therapeutic agents such as taxol, penicillin, and quinine, to name a few. Specific organisms found in nature have developed the ability to produce secondary metabolites in response to the challenges and needs that are encountered in their particular environment. In particular, through the random recombination and mutation of existing genetic material, the organism is able, in a combinatorial sense, to generate new biosynthetic enzymes that catalyze the assembly of new organic compounds (see, Verdine “The Combinatorial Chemistry of Nature” Nature, 1996, 384, 11).
  • Clearly, the ability to generate a diverse array of compounds reminiscent of these natural products would be desirable to increase the arsenal of available small molecules available for testing and use as therapeutic agents. Just as many scientists involved in the discovery and isolation of new natural products sample organisms from many different environments such as coral reefs, deep-sea hydrothermal vents, and tropical rainforests in their quest for structural diversity, both biologists and chemists have been searching for new ways to achieve this structural diversity by manipulating genetic material directly, or by generating novel synthetic pathways, respectively.
  • For example, certain researchers have attempted to alter the catalytic capability of synthetic enzymes that naturally produce interesting biologically active compounds by making specific changes to genes encoding particular enzymes (see, for example, Cortes et al., Science 268:1487, 1995; Kao et al., J. Am. Chem. Soc. 117:9105, 1995; Donadio et al., Science 252:675, 1991; WO 93/1363; U.S. Pat. No. 5,824,513; WO 98/49315; U.S. Pat. No. 5,652,116; U.S. Pat. No. 5,824,774; WO 98/51695; U.S. Pat. No. 5,795,738; and WO 98/01546). The hope is that, by modifying the gene encoding the synthetic enzyme, the researchers will be able to generate new enzymes with altered synthetic characteristics, which new enzymes will in turn generate new chemical compounds that are related to those produced by the naturally-occurring enzymes, and therefore are likely to have similar desirable biological activities.
  • Concurrently, several groups have also been interested in generating combinatorial libraries of compounds synthesized using novel synthetic methods. Specifically, in many cases, researchers have developed “biased” libraries, in which all members share a particular characteristic, such as an ability to interact with a particular target ligand, or a characteristic structural feature designed to mimic a particular aspect of a class of natural compounds. For example, a number of libraries have been designed to mimic one or more features of natural peptides. Such “peptidomimetic” libraries include phthalimido libraries (WO 97/22594), thiophene libraries (WO 97/40034), benzodiazopene libraries (U.S. Pat. No. 5,288,514), libraries formed by the sequential reaction of dienes (WO 96/03424), thiazolidinone libraries, libraries of metathiazanones and their derivatives (U.S. Pat. No. 5,549,974), and azatide libraries (WO 97/35199) (for review of peptidomimetic technologies, see Gante, J., Angew. Chem. Int. Ed. Engl. 1994, 33, 1699-1720 and references cited therein). Each of these libraries has provided solid phase synthetic strategies for compounds possessing specific core functionalities, but none achieves the complexity of structure found in natural products, or in other lead compounds prepared through traditional chemical synthetic routes. Complex natural products commonly contain several different functionalities and often are rich in stereochemical complexity. Such diversity and complexity is difficult to achieve if the synthesis is restricted to compounds containing a specific core functionality.
  • Clearly, there remains a need to develop an efficient and powerful system for the generation of large numbers of compounds having unprecedented stereochemical, structural, topological and functional diversity. The present invention provides a unique method in which both the tools provided by nature and modern organic synthesis can be utilized.
  • SUMMARY OF THE INVENTION
  • The present invention provides a method for merging combinatorial biosynthesis incorporated above with techniques of synthetic organic chemistry. In general, this method, combinatorial biology, involves 1) providing “starter units”, wherein the starter units are capable of being accepted by the modular biosynthetic enzymatic machinery, and have incorporated therein a “functional handle” capable of reacting with specific functionality present on a solid support; 2) feeding these “starter units” into the modular biosynthetic enzymatic machinery, in vivo or in vitro, to obtain complex template molecules; and 3) further functionalizing the complex template molecules using synthetic organic chemistry to provide a collection of complex “unnatural” natural products having structural, topological, stereochemical and functional diversity.
  • In a preferred embodiment, the starter units are attached to solid support units prior to feeding the starter units into the modular biosynthetic enzymatic machinery, and thus the support bound starter units are fed into the biosynthetic enzymatic machinery to generate a collection of complex template structures. These template structures thus generated can then be further functionalized using synthetic organic chemistry, or can be further functionalized using any combination of synthetic organic chemistry and reintroduction into the biosythetic enzymatic machinery.
  • In another preferred embodiment, the starter units are fed to the modular biosynthetic enzymatic machinery prior to being attached to the solid support, and thus template structures are generated. In particularly preferred embodiments specific functionalities can also be incorporated into the template structures via the original starter unit capable of being recognized by an antibody and then purified. Alternatively or additionally, these templates can then be attached to solid support units and further functionalized using synthetic organic chemistry or any combination of synthetic organic chemistry and the biosynthetic enzymatic machinery.
  • DESCRIPTION OF THE DRAWING
  • FIG. 1 depicts the biosynthesis of several erythromycin derivatives using several different starter units.
  • FIG. 2 depicts potential starter units with functional handles classified by the biosynthetic pathway.
  • FIG. 3 depicts the functionalization of an iodoaryl compound to generate an arylacetylene via Sonogashiro/Castro-Stephens coupling reaction.
  • FIG. 4 depicts certain preferred embodiments of the method of the present invention.
  • FIGS. 5A through 5C depict specific complex template structures capable of further diversification using synthetic organic chemistry or biosynthetic pathways.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Recognizing the desirability of utilizing both the efficient and powerful methods of natural products biosynthesis and the the diverse repertoire of reactions available in synthetic organic chemistry, a method for merging combinatorial biosynthesis incorporated above with techniques of synthetic organic chemistry is provided. In general, this method, combinatorial biology, involves 1) providing “starter units”, wherein the starter units are capable of being accepted by the modular biosynthetic enzymatic machinery, and have incorporated therein a “functional handle” capable of reacting with specific functionality present on a solid support; 2) feeding these “starter units” into the modular biosynthetic enzymatic machinery, in vivo or in vitro, to obtain complex template molecules; and 3) further functionalizing the complex template molecules using synthetic organic chemistry to provide a collection of complex “unnatural” natural products having structural, topological, stereochemical and functional diversity. As used herein, the term “starter unit” comprises any compound that can be incorporated into the biosynthetic pathway. For example, certain biosynthetic enzymes, such as polyketide synthases, utilize two different classes of “starter units”, specifically “initiator” molecules and “extender“molecules, typically acetates or propionates. For the purposes of the present invention, either category, “initiator” or “extender” qualifies as a “starter” molecule.
  • As one of ordinary skill in the art will realize, because the starter units have incorporated therein a functional handle, they, or any of the products generated from these starter units, are capable of being attached to solid support units at any stage in the combinatorial biosynthetic pathway. In one preferred embodiment, the starter units are attached to solid support units prior to feeding the starter units into the modular biosynthetic enzymatic machinery, and thus the support bound starter units are fed into the biosynthetic enzymatic machinery to generate a collection of complex template structures. These template structures thus generated can then be further functionalized using synthetic organic chemistry, or can be further functionalized using any combination of synthetic organic chemistry and reintroduction into the biosynthetic enzymatic machinery. In another preferred embodiment, the starter units are fed to the modular biosynthetic enzymatic machinery prior to being attached to the solid support, and thus template structures are generated. In particularly preferred embodiments specific functionalities can also be incorporated into the template structures via the original starter unit capable of being recognized by an antibody and then purified. Alternatively or additionally, these templates can then be attached to solid support units and further functionalized using synthetic organic chemistry or any combination of synthetic organic chemistry and the biosynthetic enzymatic machinery.
  • Thus, the present invention represents a broadening of the concept of combinatorial biosynthesis to incorporate the advantages of organic synthetic techniques on the solid phase to generate increasingly complex “unnatural” natural products. Various characteristics of the starter units and the reactions utilized in preferred embodiments of the present invention are discussed in more detail below; certain examples of the method of the present invention are also presented.
  • Biosynthetic Enzymatic Machinery
  • In principle, the inventive combinatorial biology methods may be applied to any biosynthetic pathway in which the synthetic enzymes will accept inventive starter molecules. In certain embodiments of the invention, the starter molecules are provided to living cells in which the synthetic enzymes are operating, and synthetic reactions in accordance with the present invention are performed in vivo. Alternatively, the biosynthetic pathway may be reproduced in vitro, and the starter molecules may be provided to the synthetic enzymes in that context. Preferred biosynthetic pathways to which the inventive technology may be applied include the animal fatty acid synthase pathway, the polyketide synthase pathway, the peptide synthetase pathway, and the terpene (or isoprenoid) synthase pathway. In certain preferred embodiments of the invention, the naturally-occurring synthetic enzymes are employed and are simply provided with non-natural starter molecules as described herein.
  • Alternatively, as mentioned above, various researchers have made modifications to certain preferred biosynthetic enzymes that alter their catalytic properties (see, for example, Cortes et al., Science 268:1487, 1995; Kao et al., J. Am. Chem. Soc. 117:9105, 1995; Donadio et al., Science 252:675, 1991; WO 93/1363; U.S. Pat. No. 5,824,513; WO 98/49315; U.S. Pat. No. 5,652,116; U.S. Pat. No. 5,824,774; WO 98/51695; U.S. Pat. No. 5,795,738; and WO 98/01546). Moreover, U.S. patent application Ser. No. 09/225,990, entitled “Improved DNA Cloning”, filed on even date herewith and incorporated herein by reference, describes a powerful system for the production of modified versions of biosynthetic enzymes, and in particular for the production of libraries of modified enzymes.
  • Preferred embodiments of the present invention utilize such modified enzymes, and preferably libraries of modified enzymes, to catalyze synthetic reactions with inventive starter molecules.
  • To mention but one particularly preferred embodiment, the system described in the above-mentioned “Improved DNA Cloning” patent application can be utilized to generate a library of class I polyketide synthase enzymes in which a particular “AT” domain responsible for choosing an inventive altered starter molecule has been shuffled to a variety of different positions in the molecule. Exposure of such an enzyme library to the appropriate collection of natural and inventive starter and extender molecules will result in incorporation of inventive molecules at various locations in the polyketide-type compound being synthesized, so that a wide variety of different polyketide-type molecules can be produced by subsequent combinatorialization of the compounds generated by the synthetic enzyme.
  • Starter Units
  • As discussed above, the method of the present invention utilizes any combination of enzymatic machinery that can be employed for specific classes of biosynthetic reaction pathways. In determining the specific “starter units” that will be utilized in the synthesis, consideration must also be made to the desired biosynthetic pathway to employ, and thus a desired family of compounds to be synthesized. For example, specific biosynthetic pathways such as polyketide synthases and peptide synthases, utilize particular starter units known to be accepted by the modular enzymes to produce a variety of natural products. In but one example, carboxylic acid building blocks having differing functional moieties such as methyl, ethyl, propyl groups are utilized by modular polyketide synthases to yield topologically, functionally and stereochemically diverse structures such as 6-deoxyerythronolide B and tylactone (see, Khosla, Chem. Rev. 1997, 97, 2577). Similarly, as shown in FIG. 1, functionalized thioesters are utilized to generate a series of derivatives having structures similar to erythromycin (see, Khosla, Chem. Rev. 1997, 97, 2577). As one of ordinary skill in the art will realize, the modular enzymes that are produced by the shuffling may not result in the ability to predict the specific starter units that will be incorporated into the enzymatic machinery. Thus, the ability of a desired or random set of starter units to become attached to the solid support and subsequently diversified using combinatorial techniques (split-pool synthesis) becomes particularly important in identifyingfunctional starter units.
  • Clearly, as mentioned, each of the starter units provided must be capable of being accepted by the enzymes “machinery”, and thus the functionality and structural topology must be compatible with the biosynthetic pathway. In but one example, as shown in FIG. 2, it would be desirable for a terpene-based pathway to utilize functionalized derivatives of a famasyl pyrophosphate analog. Additionally, for an amino-acid based pathway (peptide synthases), it would be desirable to utilize functionalized derivatives of amino acids. FIG. 2 additionally provides a collection of suitable “starter units” classified according to their utility in a specific biosynthetic pathway. Furthermore, these units can be derivatized and combinatorialized at a stage prior to feeding the units into the enzymatic machinery to produce structures having more diverse functionalities, or to produce structures having more complex topology. Thus, any structure may be utilized as a “starter unit”, regardless of the complexity and functional diversity of the compound, provided that the starter unit is capable of being utilized by the enzymatic pathway.
  • In addition to the selection of suitable starter units that will ultimately be accepted by the enzymatic machinery, it is also necessary to ensure that each of the “starter units” that are fed into the modular biosynthetic enzymatic “machinery” preferably contains a suitable functional “handle” capable of attachment to functionality present on the solid phase. FIG. 2 also depicts exemplary starter units having alkynes incorporated therein as functional handles. This can be effected by modifying the starter units that will be utilized in a particular biosynthetic pathway to incorporate the specific desired functionality for coupling to the solid support. As one of ordinary skill in the art will realize, attachment to the solid phase can occur prior to feeding the starter units into the enzymatic machinery, or after feeding the starter units into the enzymatic machinery to generate complex template structures to be attached to the solid support. Because attachment can occur prior to or after exposure to the enzymatic machinery, it is particularly preferred that the functional handle is chemically robust and thus is capable of withstanding any of the reaction conditions encountered in the enzymatic machinery. For this reason, particularly robust functionalities such as alkynes, olefins and iodoalkenes, are particularly preferred, although the method of the present invention is not limited to these functionalities.
  • In an exemplary embodiment, the starter units utilized in the present invention have alkyne functionalities incorporated therein as handles for attachment to the solid support. To illustrate the incorporation of “handles” into the starter units, FIG. 3 depicts the use of the Sonagashiro/Castro-Stephens reaction, in which unactivated aryl halides react with copper acetylides to give good yields of arylacetylenes, for the conversion of an aryl iodide to an aryl acetylene in the iodo substituted aryl thioester derivative.
  • An additional important matter to take into consideration when utilizing a starter unit having “handles”, is the number of “handles” that will ultimately be incorporated into the complex template as a result of the biosynthesis. For example, if a simpler (less structurally complex) starter unit is utilized (for example one that is used in successive condensation reactions, as exemplified in the polyketide synthases) a larger number of handles will be incorporated. Thus, if one were to incorporate a handle into a starter unit that is utilized in successive “rounds” by the enzymatic machinery, a template structure would result having many handles incorporated therein. Thus, to overcome this problem, it is preferable to 1) utilize starter units that are only incorporated once, as depicted in FIGS. 2 and 3 by the use of the aryl functionality, and as may be dictated by the selectivity of specific reactions in the enzymatic pathway; 2) to incorporate the handle into a limited number of starter units (for example, one or two units) involved in the synthesis, or 3) to utilize more complex starter units, as depicted in FIG. 2, for the polyketide pathway, and thus the enzymatic machinery does not need to utilize as many of the starter units and therefore fewer handles will be incorporated. As one of ordinary skill in the art will realize, when selecting specific starters it is necessary to take into consideration the specific enzymatic biosynthetic pathway to be utilized (and the specificity of incorporation of certain starters) and the number of “handles” desired in the resulting template structure. Once the “handles” have been incorporated into the “starter units”, the starter units can either be fed directly into the enzymatic machinery or coupled directly to the solid support. Whether the starter unit or the template structure is utilized for coupling to the solid support, (which, as one of ordinary skill in the art will realize, also has an alkyne, or other desirable functionality, bound thereto via a cleavable bond utilizing standard synthetic organic techniques) the two alkynes incorporated can then be coupled, in a preferred embodiment, using a Glaser Coupling reaction. Specifically, in this reaction, the addition of copper (II) acetate to the reaction medium effects coupling of the two components to yield a solid support having bound thereto a starter unit, or a template structure, via a diyne functionality. In other exemplary embodiments, suitable functional handles which can also be easily incorporated into starter units and solid support units using standard techniques of synthetic organic chemistry, include olefins and iodoalkenes. Thus, coupling of the components can be effected using olefin metathesis and Stille Coupling reactions, respectively. One of ordinary skill in the art will realize that although the abovementioned functionalities are particularly preferred, other functionalities that will not interfere with, or be altered by, the chemistry being employed by the enzymatic modular machinery may also be utilized.
  • Combinatorial Bioorganic Synthesis
  • Once the selection of desired starting materials is achieved and functional handles are incorporated therein for attachment to the solid phase and optionally for purification purposes, several variations of the present invention may be employed to obtain “unnatural” natural products. FIG. 4 refers to preferred embodiments of the present invention and a discussion of each of these embodiments with reference to FIG. 4 is presented below.
  • As shown in FIG. 4, genetic manipulation of the modular enzymatic machinery, yields a mutated biosynthetic pathway to be utilized for the generation of novel “unnatural” natural products. Once one or more desired mutated biosynthetic pathways are developed, either randomly or with a particular target in mind, as discussed above, the tools of synthetic organic chemistry can be employed prior to, concurrently with, or after exposure to the enzymatic machinery to further diversify and increase the universe of “unnatural” natural products that can be generated. Specifically, referring to FIG. 4, selected starter units can be fed into this mutated biosynthetic pathway in two different ways according to different embodiments of the present invention.
  • In one particularly preferred embodiment, as shown by pathway A, the selected starter units having the functional handles incorporated therein can be fed directly into the mutated biosynthetic enzymatic machinery. Thus, after exposure to the enzymatic machinery, a unique template compound can be obtained and at this stage can be purified, preferably using an antibody recognition element, or can also be attached to a solid support unit. Subsequently, after attachment to a solid support unit, the template could be reintroduced into the enzymatic machinery (same or different) to thus obtain a modified template. Alternatively, and/or additionally, the template could be utilized in split-pool organic synthesis to generate combinatorial libraries of complex “unnatural” natural products.
  • In another particularly preferred embodiment, as shown in pathway B, the selected starter units having the functional handles incorporated therein can be attached to the solid support prior to being exposed to the biosynthetic enzymatic machinery. Alternatively, or additionally, a collection of starter units could be generated using combinatorial synthetic organic chemistry. After one or more starter units are fed into the enzymatic machinery, the starter units are transformed into a support bound template structure. As FIG. 4 depicts, the template structure resulting from an initial exposure to a single biosynthetic pathway could be reexposed to the same biosynthetic or to another biosynthetic pathway to further modify the structure. Alternatively, or additionally, the solid support template structure could be diversified using split and pool techniques and synthetic organic chemistry. As one of ordinary skill in the art will realize, any combination of the enzymatic machinery and split-pool synthetic organic techniques can be employed to increase the structural, functional, topological and stereochemical diversity to generate a collection of unique “unnatural” natural products.
  • Referring to the embodiments discussed above, either split-pool or parallel synthesis methods can be employed at each stage of the inventive method to provide a desired collection of compounds. For example, if the starter unit is not initially attached to the solid support a parallel synthesis technique is preferably utilized so that the product resulting from the enzymatic machinery can be identified using spatial encoding methods. Additionally, subsequent identification of compounds using standard methods such as nuclear magnetic resonance spectroscopy or mass spectrometry can also be employed to identify specific compounds. Depending on the size of the library of compounds desired for the synthesis, the identification of individual compounds may be prohibitively time consuming and therefore a spatial encoding method may be more particularly preferred.
  • As discussed above, in one embodiment of the invention, the template structures are generated in solution, rather than on a solid support unit. In a preferred embodiment, for the generation of a collection of compounds in solution, a parallel synthesis technique is utilized, in which all of the products are assembled separately in their own reaction vessels. In a particularly preferred parallel synthesis procedure, a microtitre plate containing n rows and m columns of tiny wells which are capable of holding a few milliliters of the solvent in which the reaction will occur, is utilized. One of ordinary skill in the art will realize that this particular procedure is most useful when smaller libraries are desired, and the specific wells can provide a ready means to identify the library members in a particular well.
  • In another more particularly preferred embodiment of the present invention, a solid phase synthesis technique is utilized for the biosynthesis of the templates and the diversified structures, or alternatively for the synthesis of the diversified structures produced from template structures generated in solution as described above. As discussed in detail, the starter units or the template structures are attached to the solid phase directly or though a linking unit, depending on the stage of the procedure a solid phase synthesis is desired. Advantages of solid phase techniques, most particularly at the stage when the template structures are functionalized using synthetic organic techniques, include the ability to more easily conduct multi-step reactions and the ability to drive reactions to completion because excess reagents can be utilized and the unreacted reagent washed away. Perhaps one of the most significant advantages of solid phase synthesis is the ability to use a technique called “split and pool”, in addition to the parallel synthesis technique, developed by Furka. (Furka et al., Abstr. 14th Int. Congr. Biochem., Prague, Czechoslovakia, 1988, 5, 47; Furka et al., Int. J. Pept. Protein Res. 1991, 37, 487; Sebestyen et al., Bioorg. Med. Chem. Lett., 1993, 3, 413.) In this technique, a mixture of related compounds can be made in the same reaction vessel, thus substantially reducing the number of containers required for the synthesis of very large libraries, such as those containing as many as or more than one million library members. As an example, the solid support templates or starter units can be divided into n vessels, where n represents the number species of reagent A, or the number of different biosynthetic pathways created by the shuffling procedure, to be reacted with the template structures or starter units. After reaction, the contents from n vessels are combined and then split into m vessels, where m represents the number of species of reagent B, or the number of different biosynthetic pathways created by the shuffling procedure, to be reacted with the scaffold structures. This procedure is repeated until a desired collection of structures is obtained to yield a library of “unnatural” natural products.
  • The use of solid phase techniques in the present invention may also include the use of a specific encoding technique. Specific encoding techniques have been reviewed by Czarnik. (Czarnik, A. W., Current Opinion in Chemical Biology, 1997, 1, 60.) As used in the present invention, an encoding technique involves the use of a particular “identifying agent” attached to the solid support, which enables the determination of the structure of a specific library member without reference to its spatial coordinates. One of ordinary skill in the art will also realize that if smaller solid phase libraries are generated in specific reaction wells, such as 96 well plates, or on plastic pins, the reaction history of these library members may also be identified by their spatial coordinates in the particular plate, and thus are spatially encoded. It is most preferred, however for large combinatorial libraries, to use an alternative encoding technique to record the specific reaction history.
  • Examples of particularly preferred alternative encoding techniques that can be utilized in the present invention include, but are not limited to, spatial encoding techniques, graphical encoding techniques, including the “tea bag” method, chemical encoding methods, and spectrophotometric encoding methods. Spatial encoding refers to recording a reaction's history based on its location. Graphical encoding techniques involve the coding of each synthesis platform to permit the generation of a relational database. Examples of preferred spectrophotometic encoding methods include the use of mass spectroscopy, fluorescence emission, and nuclear magnetic resonance spectroscopy. In a most preferred embodiment, chemical encoding methods are utilized, which uses the structure of the reaction product to code for its identity. Decoding using this method can be performed on the solid phase or off of the solid phase. One of ordinary skill in the art will realize that the particular encoding method to be used in the present invention must be selected based upon the number of library members desired, and the reaction chemistry employed.
  • Subsequent characterization of the library members, which can include either the scaffolds obtained after the biosynthetic pathway or the complex molecules obtained after diversification using synthetic organic chemistry, can be performed using standard analytical techniques, such as mass spectrometry, Nuclear Magnetic Resonance Spectroscopy, and gas chromatography. One of ordinary skill in the art will realize that the selection of a particular analytical technique will depend upon whether the inventive library members are in the solution phase or on the solid phase.
  • Reactions at Latent Functionality in the Inventive Templates to Generate “Nonnatural” Compounds
  • Once the inventive templates have been synthesized as discussed above, diversification reactions may be employed at each of the different latent functionality sites present in the template structures. As mentioned previously, these functionalized templates may then also be reintroduced into the enzymatic machinery for further functionalization and structural changes, as well as be further functionalized using synthetic organic chemistry, until a desired collection of compounds is obtained. One of ordinary skill in the art will appreciate that at any stage the reactivity of a particular functionality present in the template structure must be considered when selecting particular reagents for diversification.
  • FIG. 5 depicts specific natural products which are capable of being generated using the method of the present invention, or alternatively derivatives of which are also capable of being generated using the method of the present invention. Specifically, these structures exemplify the variety of sites of latent functionality at which diversification can be achieved using synthetic combinatorial techniques. As discussed previously, this can be achieved using solution or solid phase methods, using parallel or split-pool techniques. It is particularly preferred, however, to utilize solid phase split-pool techniques. Examples of specific reactions to which some or all of the systems depicted in FIG. 5 can be subjected to in solution or on the solid support include, but are not limited to, i) addition of nucleophiles (such as primary and secondary amines), ii) functionalization of free hydroxyls with electrophiles (for examples isocyanates, anhydrides, or acid chlorides, iii) opening of epoxides with nucleophiles, such as amines, under ytterbium catalysis, iv) functionalization of aromatic rings, specifically functionalization at an aryl iodide by conversion to such structures as amines, amides, aromatic rings, alkenes, alkynes, and heterocycles using palladium catalyzed chemistry such as Buchwald-Hartwig aminations, Heck and Stille couplings, Sonogashira/Castro-Stephens couplings, Suzuki and Stille couplings, and carbonylations. Furthermore, resulting aryl alkynes can undergo rhodium-catalyzed hydroacylation and azide cycloaddition and nitrone and nitrile oxide cycloadditions. Other examples of diversification reactions at potential sites include reactions at amines and amides. For example, amides may be functionalized using a Mitsunobu reaction to generate alcohols such as straight chain, branched, and cyclic alcohols.
  • Additionally, for each of the compounds produced by the inventive method, further reactions may be employed to attach biomolecules (such as polysaccharides, nucleic acids, or peptides) or polymers to appropriate functionalities.
  • One of ordinary skill in the art will realize that the above examples are representative of the reactions that can be used to diversify not only the templates, but also the starter units, of the present invention and are not intended to be exclusive. Rather, all equivalents thereof are intended to be within the scope of the presently claimed invention. A skilled artisan in the field of synthetic organic chemistry will be able to readily identify those reagents capable of reacting to create further diversity at selected sites in the inventive template structures and starter units to generate compounds and libraries of compounds reminiscent of natural products. The inventive method is particularly useful for the generation of such compounds because it incorporates the efficiency and creativity of a method for manipulating the enzymatic reactions that produce such complex structures in nature with the arsenal of reactions available using synthetic organic techniques. For example, the generation of complex templates can be difficult utilizing only synthetic organic techniques, however, nature efficiently and elegantly provides these templates. Combining this with synthetic organic chemistry enables the use of reactions, such as palladium catalyzed reactions, that are not available in nature and thus the best of both systems can be utilized to generate compounds having unprecedented structural, topological, stereochemical and functional diversity.
  • Uses
  • The methods, compounds and libraries generated by the method of the present invention can be utilized in various disciplines. For example, the complex molecules generated in the method of the present invention may modulate the biological activity of a biological target, such as a protein, nucleic acid, lipid or combination thereof. In one preferred embodiment, the compounds generated by the method of the invention are utilized in chemical genetics assays to alter, i.e. inhibit or initiate, the action of such biological molecules. Alternatively or additionally, the compounds may be used in in vitro assays, or any other system that allows detection of a chemical or biological function.
  • In a particularly preferred embodiment of the invention, one or more inventive compounds is contacted with a biological target having a detectable biochemical activity. Such biological targets include, for example, enzymes, receptors, subunits involved in the formation of multimeric complexes. Such multimeric complex subunits may be characterized by catalytic capabilities (such as, for example, an ability to catalyze substrate conversion), or may alternatively be primarily active in binding to one or more other molecule. The biological target can be provided in the form of a purified or semi-purified composition, a cell lysate, a whole cell or tissue, or even a whole organism. The level of biochemical activity is detected in the presence of the compound, and a statistically significant change in the biochemical activity, relative to the level of biochemical activity in the absence of the compound, identifies the compound as a modulator, e.g. inhibitor or potentiator of the biological activity of the target protein. In some cases, particularly where assays are done on whole cells or organisms, the effect of the chemical compound may be to alter the amount, in addition to or instead of the activity, of the particular biological target. “Modulators”, therefore, are chemical compounds that alter the level of activity of a particular target molecule.
  • In one particularly preferred embodiment of the present invention, multiple compounds are assayed simultaneously in a high-throughput format, preferably allowing simultaneous analysis of at least 500,000 compounds, preferably at least 1,000,000 compounds, and most preferably at least or more than 2,000,000 compounds.
  • As discussed above, once a specific desired effect on a biological target has been associated with a particular compound of the inventive library, the compounds of the present invention may be utilized as a therapeutic agent for a particular medical condition. A therapeutic agent for use in the present invention may include any pharmacologically active substances that produce a local or systemic effect in animals, preferably mammals, or humans. The term thus means any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or in the enhancement of desirable physical or mental development and conditions in an animal or human. The therapeutic agent may be administered orally, topically or via injection by itself, or additionally may be provided as a pharmaceutical composition comprising the therapeutic agent and a biologically acceptable carrier. The inventive compositions can be, but are not limited to aqueous solutions, emulsions, creams, ointments, suspensions, gels, and liposomal suspensions. Particularly preferred biologically acceptable carriers include but are not limited to water, saline, Ringer's solution, dextrose solution and solutions of ethanol, glucose, sucrose, dextran, mannose, mannitol, sorbitol, polyethylene glycol (PEG), phosphate, acetate, gelatin, collagen, Carbopol, and vegetable oils. It is also possible to include suitable preservatives, stabilizers, antioxidants, antimicrobials, and buffering agents, for example including but not limited to BHA, BHT, citric acid, ascorbic acid, and tetracycline. The therapeutic agents of the presently claimed invention may also be incorporated or encapsulated in a suitable polymer matrix or membrane, thus providing a sustained-release delivery device suitable for implantation near the site to be treated locally.
  • As one of ordinary skill in the art will realize, the amount of the therapeutic agent required to treat any particular disorder will of course vary depending upon the nature and severity of the disorder, the age and condition of the subject, and other factors readily determined by one or ordinary skill in the art.
  • In alternative embodiments, the compounds and libraries of the present invention may also be used for the development of cosmetics, food additives, pesticides, and lubricants to name a few. Furthermore, the compounds and libraries of the present invention may also be used for the development of novel catalysts and materials. For example, the inventive compounds may be useful as ligands for transition metal catalysts and the inventive libraries may be useful for the rapid identification of novel ligands. These compounds and libraries of compounds may also function by acting in concert with a particular transition metal catalyst to effect a particular desired chemical reaction. Additionally, the inventive compounds and libraries of compounds are also useful in the area of materials science. Because of the reactive moieties present in these compounds, molecules such as lipids and other polymeric materials may be attached and thus generate potentially important biomaterials.
  • One of ordinary skill in the art will realize that the present invention is not intended to be limited to the abovementioned uses, but rather may be employed in many contexts and disciplines.

Claims (22)

1. A method for the combinatorial biosynthesis of one or more compounds comprising:
a) providing one or more starter units, wherein said one or more starter units have incorporated therein a functional handle that reacts with a functionality present on a solid support unit, the starter units being accepted as substrates for one or more modular biosynthetic enzymatic machinery systems;
b) attaching said one or more starter units to a solid support unit to provide one or more support bound starter units;
c) providing said one or more support bound starter units to said one or more biosynthetic enzymatic machinery systems in vitro to generate a collection of template structures, wherein the biosynthetic enzymatic machinery system is selected from the group consisting of natural and modified polyketide synthases, natural and modified peptide synthetases, natural and modified terpene synthases, and natural and modified animal fatty acid synthases;
d) functionalizing said template structures using synthetic organic chemistry; and
e) repeating steps c) and/or d) until a desired support bound collection of structures is generated.
2. The method of claim 1 further comprising functionalizing said support bound collection of structures generated in step e) to provide a support bound collection of unnatural natural products.
3. A method for the combinatorial biosynthesis of one or more compounds comprising:
a) providing one or more starter units, wherein said one or more starter units have incorporated therein a functional handle that reacts with a functionality present on a solid support unit, the starter units being accepted as substrates for one or more modular biosynthetic enzymatic machinery systems;
b) attaching said one or more starter units to a solid support unit to provide one or more support bound starter units;
c) providing said one or more support bound starter units to said one or more biosynthetic enzymatic machinery systems in vitro to generate a collection of template structures, wherein the biosynthetic enzymatic machinery system is selected from the group consisting of natural and modified polyketide synthases, natural and modified peptide synthetases, natural and modified terpene synthases, and natural and modified animal fatty acid synthases; and
d) functionalizing said collection of template structures to provide a support bound collection of unnatural natural products.
4. The method of claim 1 further comprising the step of cleaving said support bound collection of structures from said solid support unit.
5. The method of claim 2 or 3 further comprising the step of cleaving said support bound collection of unnatural natural products from said solid support unit.
6. The method of claim 1, 2 or 3 wherein the functional handle is a functionality which includes an alkyne, an olefin or an iodoalkene group.
7. The method of claim 1, 2 or 3 wherein the step of attaching the starter units to the solid support unit is effected by a chemical reaction which includes Glaser coupling, olefin metathesis or Stille coupling reaction.
8. The method of claim 1, 2 or 3 wherein the biosynthetic enzymatic machinery systems comprise one or more naturally-occurring synthetic enzymes.
9. The method of claim 8 wherein the biosynthetic enzymatic machinery systems comprise one or more enzymes which include fatty acid synthase, polyketide synthase, peptide synthetase or terpene (or isoprenoid) synthase.
10. The method of claim 1, 2 or 3 wherein the biosynthetic enzymatic machinery systems comprise one or more modified enzymes.
11. The method of claim 10 wherein the modified enzyme is a genetically modified enzyme.
12. The method of claim 10 wherein the modified enzyme is a class I polyketide synthase enzyme.
13. The method of claim 1, 2 or 3 wherein one or more starter units is purified via antibody recognition.
14. The method of claim 1, 2 or 3 wherein one or more template structures is purified via antibody recognition.
15. The method of claim 1, 2 or 3 wherein the step of functionalizing said template structures is carried out using combinatorial techniques including, but not limited to, parallel synthesis and split-and-pool synthesis.
16. The method of claim 1, 2 or 3 wherein the step of functionalizing the template structures includes attaching a biomolecule to said template structures.
17. The method of claim 16 wherein the biomolecule includes polysaccharides, nucleic acids, peptides, and polymers.
18. The method of claim 1, 2 or 3 further comprising the step of recording the reaction history using an encoding technique.
19. The method of claim 18 wherein the encoding technique is selected from the group consisting of spatial encoding techniques, graphical encoding techniques, chemical encoding techniques and spectrometric encoding techniques.
20. The method of claim 19 wherein the spectrometric encoding technique is selected from the group consisting of mass spectroscopy, fluorescence emission and nuclear magnetic resonance spectroscopy.
22. A combinatorial biosynthesis method of preparing one or more compounds comprising the steps of:
a) reacting one or more amino acid derivatives with a solid support via a Glaser coupling, olefin metathesis or a Stille coupling, wherein the amino acid derivative includes a functional handle selected from the group consisting of an alkyne, olefin and iodoalkene groups and the solid support includes one or more alkyne or olefin groups, to form support bound amino acid derivatives;
b) catalyzing an in vitro reaction between two or more amino acid derivatives using a peptide synthetase, thereby generating a collection of template structures;
c) functionalizing said template structures using one or more reaction selected from the group consisting of nucleophilic addition, functionalization of hydroxyl groups with electrophiles, Buchwald-Hartwig aminations, Heck coupling, Stille coupling, Sonogashira/Catro-Stephens coupling, Suzuki coupling, carbonylations, Mitsunobu reaction, hydroacylation, azide cycloaddition, nitrone cycloaddition, nitrile oxide cycloaddition, and combinations thereof, and
d) optionally repeating steps b) and/or c), wherein at least one of the amino acid derivatives is bound to a solid support, thereby forming a collection of support bound compounds.
23. A combinatorial biosynthesis method of preparing one or more compounds comprising the steps of:
a) reacting one or more thioester derivatives with a solid support via a Glaser coupling, olefin metathesis or a Stille coupling, wherein the thioester derivative includes a functional handle selected from the group consisting of an alkyne, olefin and iodoalkene groups and the solid support includes one or more alkyne or olefin groups, to form support bound thioester derivatives;
b) catalyzing an in vitro reaction between two or more thioester derivatives using a polyketide synthase, thereby generating a collection of template structures;
c) functionalizing said template structures using one or more reaction selected from the group consisting of nucleophilic addition, functionalization of hydroxyl groups with electrophiles, Buchwald-Hartwig aminations, Heck coupling, Stille coupling, Sonogashira/Catro-Stephens coupling, Suzuki coupling, carbonylations, Mitsunobu reaction, hydroacylation, azide cycloaddition, nitrone cycloaddition nitrile oxide cycloaddition, and combinations thereof, and
d) optionally repeating steps b) and/or c), wherein at least one of the thioester derivatives is bound to a solid support, thereby forming a collection of support bound compounds.
US11/763,966 1999-01-05 2007-06-15 Combinatorial Biology Abandoned US20070269858A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/763,966 US20070269858A1 (en) 1999-01-05 2007-06-15 Combinatorial Biology

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11490999P 1999-01-05 1999-01-05
US09/225,990 US6358712B1 (en) 1999-01-05 1999-01-05 Ordered gene assembly
US47826300A 2000-01-05 2000-01-05
US11/763,966 US20070269858A1 (en) 1999-01-05 2007-06-15 Combinatorial Biology

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US47826300A Continuation 1999-01-05 2000-01-05

Publications (1)

Publication Number Publication Date
US20070269858A1 true US20070269858A1 (en) 2007-11-22

Family

ID=26812654

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/897,712 Expired - Fee Related US7579146B2 (en) 1999-01-05 2001-06-29 Nucleic acid cloning
US11/132,356 Expired - Lifetime US7439021B2 (en) 1999-01-05 2005-05-18 Nucleic acid cloning
US11/763,966 Abandoned US20070269858A1 (en) 1999-01-05 2007-06-15 Combinatorial Biology
US12/547,196 Abandoned US20090317875A1 (en) 1999-01-05 2009-08-25 Nucleic acid cloning

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/897,712 Expired - Fee Related US7579146B2 (en) 1999-01-05 2001-06-29 Nucleic acid cloning
US11/132,356 Expired - Lifetime US7439021B2 (en) 1999-01-05 2005-05-18 Nucleic acid cloning

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/547,196 Abandoned US20090317875A1 (en) 1999-01-05 2009-08-25 Nucleic acid cloning

Country Status (8)

Country Link
US (4) US7579146B2 (en)
EP (1) EP1141275B1 (en)
JP (3) JP2002537762A (en)
AT (1) ATE439437T1 (en)
AU (1) AU774306B2 (en)
CA (1) CA2360011A1 (en)
DE (1) DE60042730D1 (en)
WO (1) WO2000040715A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076655A2 (en) * 2007-12-13 2009-06-18 University Of Washington Synthetic enzymes derived from computational design
US20130071619A1 (en) * 2010-05-28 2013-03-21 Nippon Steel & Sumikin Chemical Co., Ltd. Metal fine-particle composite and method for fabricating the same

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048772A1 (en) 2000-02-10 2002-04-25 Dahiyat Bassil I. Protein design automation for protein libraries
US7315786B2 (en) 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
CA2360011A1 (en) * 1999-01-05 2000-07-13 Trustees Of Boston University Ordered gene assembly
US6692918B2 (en) 1999-09-13 2004-02-17 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences
US7846733B2 (en) 2000-06-26 2010-12-07 Nugen Technologies, Inc. Methods and compositions for transcription-based nucleic acid amplification
WO2002008408A2 (en) * 2000-07-21 2002-01-31 Trustees Of Boston University Modular vector systems
US6858413B2 (en) 2000-12-13 2005-02-22 Nugen Technologies, Inc. Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof
MXPA02012739A (en) 2001-03-09 2004-04-20 Nugen Technologies Inc Methods and compositions for amplification of rna sequences.
EP1482433A3 (en) * 2001-08-10 2006-04-12 Xencor, Inc. Protein design automation for protein libraries
ATE405676T1 (en) 2002-03-11 2008-09-15 Nugen Technologies Inc METHOD FOR GENERATING DOUBLE STRANDED DNA WITH A 3' SINGLE STRAND PORTION AND USES OF THESE COMPLEXES FOR RECOMBINATION
CA2521084A1 (en) 2003-04-14 2004-10-28 Nugen Technologies, Inc. Global amplification using a randomly primed composite primer
WO2006047669A2 (en) * 2004-10-27 2006-05-04 Monsanto Technology Llc Non-random method of gene shuffling
ATE540110T1 (en) 2004-11-11 2012-01-15 Modular Genetics Inc OLIGONUCLEOTIDE LADDER CONSTRUCTION AND SYSTEM FOR GENERATING MOLECULAR DIVERSITY
ATE483802T1 (en) * 2005-08-11 2010-10-15 Synthetic Genomics Inc METHOD FOR IN VITRO RECOMBINATION
US7723077B2 (en) 2005-08-11 2010-05-25 Synthetic Genomics, Inc. In vitro recombination method
WO2007030759A2 (en) 2005-09-07 2007-03-15 Nugen Technologies, Inc. Improved nucleic acid amplification procedure
US8053191B2 (en) 2006-08-31 2011-11-08 Westend Asset Clearinghouse Company, Llc Iterative nucleic acid assembly using activation of vector-encoded traits
US8034568B2 (en) 2008-02-12 2011-10-11 Nugen Technologies, Inc. Isothermal nucleic acid amplification methods and compositions
US7846666B2 (en) 2008-03-21 2010-12-07 Nugen Technologies, Inc. Methods of RNA amplification in the presence of DNA
US10207240B2 (en) 2009-11-03 2019-02-19 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
WO2011066185A1 (en) 2009-11-25 2011-06-03 Gen9, Inc. Microfluidic devices and methods for gene synthesis
US9217144B2 (en) 2010-01-07 2015-12-22 Gen9, Inc. Assembly of high fidelity polynucleotides
US10457935B2 (en) 2010-11-12 2019-10-29 Gen9, Inc. Protein arrays and methods of using and making the same
EP3360963B1 (en) 2010-11-12 2019-11-06 Gen9, Inc. Methods and devices for nucleic acids synthesis
AU2012300401B2 (en) * 2011-08-26 2018-02-08 Gen9, Inc. Compositions and methods for high fidelity assembly of nucleic acids
US9150853B2 (en) 2012-03-21 2015-10-06 Gen9, Inc. Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
WO2013163263A2 (en) 2012-04-24 2013-10-31 Gen9, Inc. Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
CN104685116A (en) 2012-06-25 2015-06-03 Gen9股份有限公司 Methods for nucleic acid assembly and high throughput sequencing
US10148285B1 (en) 2012-07-25 2018-12-04 Erich Schmitt Abstraction and de-abstraction of a digital data stream
US10795858B1 (en) 2014-02-18 2020-10-06 Erich Schmitt Universal abstraction and de-abstraction of a digital data stream
GB201516348D0 (en) * 2015-09-15 2015-10-28 Labgenius Ltd Compositions and methods for polynucleotide assembly
GB2566986A (en) 2017-09-29 2019-04-03 Evonetix Ltd Error detection during hybridisation of target double-stranded nucleic acid
EP3953466A1 (en) * 2019-04-10 2022-02-16 Ribbon Biolabs GmbH A library of polynucleotides

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466145A (en) * 1891-12-29 District
US4935357A (en) * 1986-02-05 1990-06-19 New England Biolabs, Inc. Universal restriction endonuclease
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116246A (en) * 1991-02-12 1992-05-26 Perry Jeffrey E Fuse block adapters for terminal blocks
US5180818A (en) * 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5270185A (en) * 1989-04-21 1993-12-14 Hoffmann-La Roche Inc. High-efficiency cloning of CDNA
US5432263A (en) * 1992-12-18 1995-07-11 Abbott Laboratories Process for producing peptides with side chains containing imidazolinylamino, tetrahydropyrimidinylamino, or alkylguanidinyl groups
US5487993A (en) * 1990-09-27 1996-01-30 Invitrogen Corporation Direct cloning of PCR amplified nucleic acids
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5523221A (en) * 1993-06-16 1996-06-04 Stratagene Method for the directional cloning of DNA
US5573913A (en) * 1994-02-28 1996-11-12 Boehringer Mannheim Gmbh 3'-RNA labelling with terminal transferase
US5595895A (en) * 1989-07-28 1997-01-21 The United States Of America As Represented By The Department Of Health And Human Services Efficient directional genetic cloning system
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5641673A (en) * 1991-01-17 1997-06-24 The General Hospital Corporation Cell ablation using trans-splicing ribozymes
US5643766A (en) * 1991-01-18 1997-07-01 Beth Israel Hospital Association Synthesis of full-length, double-stranded DNA from a single-stranded linear DNA template
US5652116A (en) * 1993-07-13 1997-07-29 Eniricerche S.P.A. Method for genetically manipulating peptide synthetases
US5660958A (en) * 1991-01-31 1997-08-26 Dai Nippon Printing Co., Ltd. Information recording medium, and information recording and reproducing method
US5667969A (en) * 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5672491A (en) * 1993-09-20 1997-09-30 The Leland Stanford Junior University Recombinant production of novel polyketides
US5688670A (en) * 1994-09-01 1997-11-18 The General Hospital Corporation Self-modifying RNA molecules and methods of making
US5698421A (en) * 1995-09-12 1997-12-16 The Ohio State Research Foundation Ribonucleoprotein particles for cleaving double-stranded DNA and inserting an RNA/DNA molecule into the cleavage site
US5712146A (en) * 1993-09-20 1998-01-27 The Leland Stanford Junior University Recombinant combinatorial genetic library for the production of novel polyketides
US5716849A (en) * 1994-06-08 1998-02-10 Novartis Finance Corporation Genes for the biosynthesis of soraphen
US5723323A (en) * 1985-03-30 1998-03-03 Kauffman; Stuart Alan Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof
US5795738A (en) * 1995-08-09 1998-08-18 Eniricerche S.P.A. Engineered peptide synthetases and their use for the non-ribosomal production of peptides
US5804418A (en) * 1996-11-19 1998-09-08 The Ohio State University Research Foundation Methods for preparing nucleotide integrases
US5824513A (en) * 1991-01-17 1998-10-20 Abbott Laboratories Recombinant DNA method for producing erythromycin analogs
US5824774A (en) * 1996-04-12 1998-10-20 Board Of Trustees Of The University Of Kentucky Chimeric isoprenoid synthases and uses thereof
US5827704A (en) * 1994-01-25 1998-10-27 The Regents Of The University Of Michigan Vectors for cloning and modification of DNA fragments
US5843718A (en) * 1993-09-20 1998-12-01 The Leland Stanford Junior University Recombinant production of novel polyketides
US5854144A (en) * 1997-11-10 1998-12-29 Manco, Inc. Cushioned liner laminate
US5935788A (en) * 1996-06-25 1999-08-10 Lifespan Biosciences, Inc. Subtractive hybridization techniques for identifying differentially expressed and commonly expressed nucleic acid
US6027894A (en) * 1994-09-16 2000-02-22 Affymetrix, Inc. Nucleic acid adapters containing a type IIs restriction site and methods of using the same
US6027895A (en) * 1995-09-12 2000-02-22 The Ohio State University Research Foundation Methods for cleaving DNA with nucleotide integrases
US6033883A (en) * 1996-12-18 2000-03-07 Kosan Biosciences, Inc. Production of polyketides in bacteria and yeast
US6297007B1 (en) * 1997-05-22 2001-10-02 Terragen Diversity Inc. Method for isolation of biosynthesis genes for bioactive molecules
US6358712B1 (en) * 1999-01-05 2002-03-19 Trustee Of Boston University Ordered gene assembly

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4661450A (en) * 1983-05-03 1987-04-28 Molecular Genetics Research And Development Limited Partnership Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5333675C1 (en) * 1986-02-25 2001-05-01 Perkin Elmer Corp Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5098837A (en) 1988-06-07 1992-03-24 Eli Lilly And Company Macrolide biosynthetic genes for use in streptomyces and other organisms
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5595985A (en) * 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5252474A (en) * 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
DE3940267A1 (en) * 1989-12-06 1991-06-13 Bayer Ag INSECTICIDES
CA2035010C (en) * 1990-01-26 1996-12-10 Keith C. Backman Method of amplifying target nucleic acids applicable to both polymerase and ligase chain reactions
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
JP3337748B2 (en) * 1992-09-25 2002-10-21 財団法人神奈川科学技術アカデミー Method for synthesizing full-length cDNA, method for producing intermediate thereof, and method for producing recombinant vector containing full-length cDNA
US5426039A (en) * 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
JP3082549B2 (en) * 1993-12-27 2000-08-28 株式会社村田製作所 Method for producing ceramic green sheet with supporting film
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6309883B1 (en) * 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) * 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US6057103A (en) * 1995-07-18 2000-05-02 Diversa Corporation Screening for novel bioactivities
US6168919B1 (en) * 1996-07-17 2001-01-02 Diversa Corporation Screening methods for enzymes and enzyme kits
US5958672A (en) * 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6030779A (en) * 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
AU6910396A (en) * 1995-08-28 1997-03-19 Alphagene, Inc. Use of a 5' positional primer to produce double-stranded dna from a dna template
US5965408A (en) * 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6939689B2 (en) * 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US7018793B1 (en) * 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6972183B1 (en) 1997-06-16 2005-12-06 Diversa Corporation Capillary array-based enzyme screening
US5939250A (en) * 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
US6083702A (en) * 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
US5928906A (en) * 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6495318B2 (en) 1996-06-17 2002-12-17 Vectorobjects, Llc Method and kits for preparing multicomponent nucleic acid constructs
CA2258570A1 (en) * 1996-06-17 1997-12-24 Biodynamics Associates Method and kits for preparing multicomponent nucleic acid constructs
US5763239A (en) * 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US5935357A (en) * 1997-02-20 1999-08-10 Gencorp Inc. Dual-weld roof membrane welding apparatus and method of using same
DE69827745T2 (en) * 1997-06-12 2005-11-10 Sloan-Kettering Institute For Cancer Research COVALENT BINDING OF DNA TO RNA STRANDS CATALYSED BY VACCINIA TOPOISOMERASE
US5856144A (en) * 1997-06-18 1999-01-05 Novagen, Inc. Direct cloning of DNA fragments
US6183740B1 (en) * 1997-08-13 2001-02-06 Diversa Corporation Recombinant bacterial phytases and uses thereof
US7078035B2 (en) * 1997-08-13 2006-07-18 Diversa Corporation Phytases, nucleic acids encoding them and methods for making and using them
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6361942B1 (en) * 1998-03-24 2002-03-26 Boston Probes, Inc. Method, kits and compositions pertaining to detection complexes
KR100282492B1 (en) * 1998-04-13 2001-02-15 윤종용 Implanter with interceptor of undesired particles
US20040005673A1 (en) * 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
CA2360011A1 (en) * 1999-01-05 2000-07-13 Trustees Of Boston University Ordered gene assembly
WO2000042559A1 (en) * 1999-01-18 2000-07-20 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6917882B2 (en) * 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7024312B1 (en) * 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7430477B2 (en) * 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7078504B2 (en) 2000-12-01 2006-07-18 Diversa Corporation Enzymes having dehalogenase activity and methods of use thereof
EP2169076B1 (en) * 2001-02-21 2016-11-02 BASF Enzymes LLC Enzymes having alpha amylase activity and methods of use thereof
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1578987A2 (en) 2001-08-03 2005-09-28 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US7232672B2 (en) * 2001-08-03 2007-06-19 Diversa Corporation P450 enzymes, nucleic acids encoding them and methods of making and using them
US7747391B2 (en) * 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
CA2501645A1 (en) 2002-10-10 2004-04-22 Diversa Corporation Proteases, nucleic acids encoding them and methods for making and using them
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2004085615A2 (en) 2003-03-20 2004-10-07 Diversa Corporation Glucosidases, nucleic acids encoding them and methods for making and using them
CN1625176B (en) * 2003-12-03 2010-04-28 华为技术有限公司 Realization method of edge to edge pseudo-line simulation protocol
BRPI0511196A (en) * 2004-05-19 2007-12-04 Maxygen Inc isolated or recombinant polypeptide, conjugate, composition, host cell, vector, methods for making a polypeptide, for making a conjugate, for reducing the copy number of a virus in virus-infected cells, for reducing the level of rna hcv, dna hbv and rna hiv in the serum of a patient infected with hcv, hbv and hiv, and use of the polypeptide, conjugate or composition
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP2008520207A (en) * 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート Protein backbone and uses thereof

Patent Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466145A (en) * 1891-12-29 District
US5824514A (en) * 1985-03-30 1998-10-20 Stuart A. Kauffman Process for the production of expression vectors comprising at least one stochastic sequence of polynucleotides
US5814476A (en) * 1985-03-30 1998-09-29 Stuart Kauffman Process for the production of stochastically-generated transcription or translation products
US5976862A (en) * 1985-03-30 1999-11-02 Ixsys Corporation Process for obtaining DNA, RNA, peptides, polypeptides, or proteins, by recombinant DNA technique
US5817483A (en) * 1985-03-30 1998-10-06 Stuart Kauffman Process for the production of stochastically-generated peptides,polypeptides or proteins having a predetermined property
US5723323A (en) * 1985-03-30 1998-03-03 Kauffman; Stuart Alan Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof
US4935357A (en) * 1986-02-05 1990-06-19 New England Biolabs, Inc. Universal restriction endonuclease
US5093246A (en) * 1986-12-03 1992-03-03 University Patents, Inc. Rna ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5270185A (en) * 1989-04-21 1993-12-14 Hoffmann-La Roche Inc. High-efficiency cloning of CDNA
US5595895A (en) * 1989-07-28 1997-01-21 The United States Of America As Represented By The Department Of Health And Human Services Efficient directional genetic cloning system
US5180818A (en) * 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5487993A (en) * 1990-09-27 1996-01-30 Invitrogen Corporation Direct cloning of PCR amplified nucleic acids
US5641673A (en) * 1991-01-17 1997-06-24 The General Hospital Corporation Cell ablation using trans-splicing ribozymes
US5824513A (en) * 1991-01-17 1998-10-20 Abbott Laboratories Recombinant DNA method for producing erythromycin analogs
US5643766A (en) * 1991-01-18 1997-07-01 Beth Israel Hospital Association Synthesis of full-length, double-stranded DNA from a single-stranded linear DNA template
US5660958A (en) * 1991-01-31 1997-08-26 Dai Nippon Printing Co., Ltd. Information recording medium, and information recording and reproducing method
US5116246A (en) * 1991-02-12 1992-05-26 Perry Jeffrey E Fuse block adapters for terminal blocks
US5432263A (en) * 1992-12-18 1995-07-11 Abbott Laboratories Process for producing peptides with side chains containing imidazolinylamino, tetrahydropyrimidinylamino, or alkylguanidinyl groups
US5523221A (en) * 1993-06-16 1996-06-04 Stratagene Method for the directional cloning of DNA
US5652116A (en) * 1993-07-13 1997-07-29 Eniricerche S.P.A. Method for genetically manipulating peptide synthetases
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5780272A (en) * 1993-09-10 1998-07-14 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US6022731A (en) * 1993-09-20 2000-02-08 The Leland Stanford Junior University Recombinant production of novel polyketides
US5672491A (en) * 1993-09-20 1997-09-30 The Leland Stanford Junior University Recombinant production of novel polyketides
US5843718A (en) * 1993-09-20 1998-12-01 The Leland Stanford Junior University Recombinant production of novel polyketides
US5712146A (en) * 1993-09-20 1998-01-27 The Leland Stanford Junior University Recombinant combinatorial genetic library for the production of novel polyketides
US5667969A (en) * 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5827704A (en) * 1994-01-25 1998-10-27 The Regents Of The University Of Michigan Vectors for cloning and modification of DNA fragments
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5573913A (en) * 1994-02-28 1996-11-12 Boehringer Mannheim Gmbh 3'-RNA labelling with terminal transferase
US5716849A (en) * 1994-06-08 1998-02-10 Novartis Finance Corporation Genes for the biosynthesis of soraphen
US5688670A (en) * 1994-09-01 1997-11-18 The General Hospital Corporation Self-modifying RNA molecules and methods of making
US6027894A (en) * 1994-09-16 2000-02-22 Affymetrix, Inc. Nucleic acid adapters containing a type IIs restriction site and methods of using the same
US5795738A (en) * 1995-08-09 1998-08-18 Eniricerche S.P.A. Engineered peptide synthetases and their use for the non-ribosomal production of peptides
US5698421A (en) * 1995-09-12 1997-12-16 The Ohio State Research Foundation Ribonucleoprotein particles for cleaving double-stranded DNA and inserting an RNA/DNA molecule into the cleavage site
US5869634A (en) * 1995-09-12 1999-02-09 The Ohio State Research Foundation Method of making an RNA particle for use in cleaving nucleic acid molecules and inserting a nucleic acid molecule into the cleavage site
US6027895A (en) * 1995-09-12 2000-02-22 The Ohio State University Research Foundation Methods for cleaving DNA with nucleotide integrases
US5824774A (en) * 1996-04-12 1998-10-20 Board Of Trustees Of The University Of Kentucky Chimeric isoprenoid synthases and uses thereof
US5935788A (en) * 1996-06-25 1999-08-10 Lifespan Biosciences, Inc. Subtractive hybridization techniques for identifying differentially expressed and commonly expressed nucleic acid
US6001608A (en) * 1996-11-19 1999-12-14 The Ohio State Research Foundation Methods of making an RNP particle having nucleotide integrase activity
US5804418A (en) * 1996-11-19 1998-09-08 The Ohio State University Research Foundation Methods for preparing nucleotide integrases
US6033883A (en) * 1996-12-18 2000-03-07 Kosan Biosciences, Inc. Production of polyketides in bacteria and yeast
US6297007B1 (en) * 1997-05-22 2001-10-02 Terragen Diversity Inc. Method for isolation of biosynthesis genes for bioactive molecules
US5854144A (en) * 1997-11-10 1998-12-29 Manco, Inc. Cushioned liner laminate
US6358712B1 (en) * 1999-01-05 2002-03-19 Trustee Of Boston University Ordered gene assembly

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076655A2 (en) * 2007-12-13 2009-06-18 University Of Washington Synthetic enzymes derived from computational design
US20090191607A1 (en) * 2007-12-13 2009-07-30 University Of Washington Synthetic enzymes derived from computational design
WO2009076655A3 (en) * 2007-12-13 2009-12-30 University Of Washington Synthetic enzymes derived from computational design
US8340951B2 (en) 2007-12-13 2012-12-25 University Of Washington Synthetic enzymes derived from computational design
US9243238B2 (en) 2007-12-13 2016-01-26 University Of Washington Synthetic enzymes derived from computational design
US20130071619A1 (en) * 2010-05-28 2013-03-21 Nippon Steel & Sumikin Chemical Co., Ltd. Metal fine-particle composite and method for fabricating the same

Also Published As

Publication number Publication date
ATE439437T1 (en) 2009-08-15
US20060105358A1 (en) 2006-05-18
WO2000040715A2 (en) 2000-07-13
US7579146B2 (en) 2009-08-25
JP2011200257A (en) 2011-10-13
JP2007075128A (en) 2007-03-29
JP2002537762A (en) 2002-11-12
EP1141275B1 (en) 2009-08-12
WO2000040715A9 (en) 2002-08-29
AU774306B2 (en) 2004-06-24
CA2360011A1 (en) 2000-07-13
US20090317875A1 (en) 2009-12-24
US7439021B2 (en) 2008-10-21
EP1141275A2 (en) 2001-10-10
WO2000040715A3 (en) 2001-02-08
US20050191623A1 (en) 2005-09-01
DE60042730D1 (en) 2009-09-24
AU3692100A (en) 2000-07-24

Similar Documents

Publication Publication Date Title
US20070269858A1 (en) Combinatorial Biology
Uttamchandani et al. Protein and small molecule microarrays: powerful tools for high-throughput proteomics
Still Discovery of sequence-selective peptide binding by synthetic receptors using encoded combinatorial libraries
O’Reilly et al. The evolution of DNA-templated synthesis as a tool for materials discovery
US5541061A (en) Methods for screening factorial chemical libraries
Gordon et al. Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions
Ni et al. Versatile approach to encoding combinatorial organic syntheses using chemically robust secondary amine tags
Breitling et al. High-density peptide arrays
Krattiger et al. Catalyst–Substrate Coimmobilization: A Strategy for Catalysts Discovery in Split‐and‐Mix Libraries
US5891737A (en) Combinatorial non-peptide libraries
Felder The challenge of preparing and testing combinatorial compound libraries in the fast lane, at the front end of drug development
Frank High-density synthetic peptide microarrays: emerging tools for functional genomics and proteomics
Harris et al. PNA encoding (PNA= peptide nucleic acid): From solution‐based libraries to organized microarrays
JPH11503720A (en) Method for producing multiple chemicals in a spatially arranged array
JPH09500007A (en) Random chemistry for new compound formation
Czarnik Peer Reviewed: Combinatorial Chemistry
Gao et al. High density peptide microarrays. In situ synthesis and applications
Gennari et al. Combinatorial libraries: Studies in molecular recognition and the quest for new catalysts
Mattes et al. Miniaturized and Automated Synthesis of Biomolecules—Overview and Perspectives
Dong et al. Mutual leveraging of proximity effects and click chemistry in chemical biology
Kofoed et al. A general method for designing combinatorial peptide libraries decodable by amino acid analysis
CN101583580B (en) Make and use of surface molecules of varied densities
US20030082830A1 (en) Synthesis of combinatorial libraries of compounds reminiscent of natural products
Schmuck et al. Combinatorial receptor finding—large and random vs. small and focused libraries
US6864048B2 (en) Factorial chemical libraries

Legal Events

Date Code Title Description
AS Assignment

Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHU

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHAIR, MATTHEW D.;REEL/FRAME:021944/0791

Effective date: 20081118

AS Assignment

Owner name: TRUSTEES OF BOSTON UNIVERSITY, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JARRELL, KEVIN A.;REEL/FRAME:021951/0552

Effective date: 20000428

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION